Min-Chul Park
Director/Board Member at ZYVERSA THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Min-Chul Park is the founder of Tme Therapeutics, Inc. He currently holds the position of Chief Executive Officer & Director at Curebio Therapeutics, Director at ZyVersa Therapeutics Operating, Inc., Independent Director at ZyVersa Therapeutics, Inc., and Assistant Professor at Inje University.
Previously, he served as Chief Executive Officer & Director at Neomics Co., Ltd., Chief Executive Officer & Director at CURE BIO Co., Ltd., and Senior Research Associate at Seoul National University.
He obtained his doctorate degree from Seoul National University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-20 | 0 ( -.--% ) | - $ | 2024-04-29 |
Min-Chul Park active positions
| Companies | Position | Start |
|---|---|---|
| ZYVERSA THERAPEUTICS, INC. | Director/Board Member | 2022-11-30 |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Director/Board Member | - |
| Inje University | Corporate Officer/Principal | - |
Former positions of Min-Chul Park
| Companies | Position | End |
|---|---|---|
CURE BIO Co., Ltd.
 CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Chief Executive Officer | 2022-03-31 |
Neomics Co., Ltd.
 Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Chief Executive Officer | - |
Training of Min-Chul Park
| Seoul National University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ZYVERSA THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Neomics Co., Ltd.
Neomics Co., Ltd. Pharmaceuticals: MajorHealth Technology Neomics Co., Ltd. develops and commercializes diagnostics and therapeutics for human incurable diseases, such as cancer. It provides services of custom antibody and protein production and offers antibody groups including in-house antibodies from aminoacyl-tRNA synthesize. The company was founded by Chi Uk In in 2005 and is headquartered in Seoul, South Korea. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
CURE BIO Co., Ltd.
CURE BIO Co., Ltd. BiotechnologyHealth Technology CURE BIO Co., Ltd. ENGAGES in the research and development of therapeutic and diagnostic products through the use of aminoacyl tRNA synthetase. The company was founded in 2002 and is headquartered in Seoul, South Korea. | Health Technology |
- Stock Market
- Insiders
- Min-Chul Park
